K
Kengo Takeuchi
Researcher at Japanese Foundation for Cancer Research
Publications - 387
Citations - 17909
Kengo Takeuchi is an academic researcher from Japanese Foundation for Cancer Research. The author has contributed to research in topics: Lymphoma & Anaplastic lymphoma kinase. The author has an hindex of 55, co-authored 343 publications receiving 15579 citations. Previous affiliations of Kengo Takeuchi include Tokyo Medical and Dental University & University of Tokyo.
Papers
More filters
Journal ArticleDOI
RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi,Manabu Soda,Yuki Togashi,Ritsuro Suzuki,Seiji Sakata,Satoko Hatano,Reimi Asaka,Wakako Hamanaka,Hironori Ninomiya,Hirofumi Uehara,Young Lim Choi,Yukitoshi Satoh,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Hiroyuki Mano,Hiroyuki Mano,Yuichi Ishikawa +17 more
TL;DR: A multivariate analysis of 1,116 adenocarcinomas containing 71 kinase-fusion–positive adenokcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase -fusion status.
Journal ArticleDOI
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi,Manabu Soda,Yoshihiro Yamashita,Toshihide Ueno,Junpei Takashima,Takahiro Nakajima,Yasushi Yatabe,Kengo Takeuchi,Toru Hamada,Hidenori Haruta,Yuichi Ishikawa,Hideki Kimura,Tetsuya Mitsudomi,Yoshiro Tanio,Hiroyuki Mano +14 more
TL;DR: The discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor are reported.
Journal ArticleDOI
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi,Young Lim Choi,Yuki Togashi,Manabu Soda,Satoko Hatano,Kentaro Inamura,Shuji Takada,Toshihide Ueno,Yoshihiro Yamashita,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Yuichi Ishikawa,Hiroyuki Mano +13 more
TL;DR: An intercalated antibody-enhanced polymer (iAEP) method that incorporates an intercalating antibody between the primary antibody to ALK and the dextran polymer-based detection reagents should prove suitable for immunohistochemical screening of tumors positive for ALK or ALK fusion proteins among pathologic archives.
Journal ArticleDOI
Integrated molecular analysis of adult T cell leukemia/lymphoma
Keisuke Kataoka,Yasunobu Nagata,Akira Kitanaka,Yuichi Shiraishi,Teppei Shimamura,Jun-ichirou Yasunaga,Yasushi Totoki,Kenichi Chiba,Aiko Sato-Otsubo,Genta Nagae,Ryohei Ishii,Satsuki Muto,Shinichi Kotani,Yosaku Watatani,June Takeda,Masashi Sanada,Hiroko Tanaka,Hiromichi Suzuki,Yusuke Sato,Yusuke Shiozawa,Tetsuichi Yoshizato,Kenichi Yoshida,Hideki Makishima,Masako Iwanaga,Guangyong Ma,Kisato Nosaka,Masakatsu Hishizawa,Hidehiro Itonaga,Yoshitaka Imaizumi,Wataru Munakata,Hideaki Ogasawara,Toshitaka Sato,Ken Sasai,Kenzo Muramoto,Marina Penova,Takahisa Kawaguchi,Hiromi Nakamura,Natsuko Hama,Kotaro Shide,Yoko Kubuki,Tomonori Hidaka,Takuro Kameda,Tsuyoshi Nakamaki,Ken Ishiyama,Shuichi Miyawaki,Sung-Soo Yoon,Kensei Tobinai,Yasushi Miyazaki,Akifumi Takaori-Kondo,Fumihiko Matsuda,Kengo Takeuchi,Osamu Nureki,Hiroyuki Aburatani,Toshiki Watanabe,Tatsuhiro Shibata,Masao Matsuoka,Satoru Miyano,Kazuya Shimoda,Seishi Ogawa +58 more
TL;DR: The identified alterations overlap significantly with the HTLV-1 Tax interactome and are highly enriched for T cell receptor–NF-κB signaling, T cell trafficking and other T cell–related pathways as well as immunosurveillance.
Journal ArticleDOI
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto,Katsuyuki Kiura,Makoto Nishio,Kazuhiko Nakagawa,Makoto Maemondo,Akira Inoue,Toyoaki Hida,Nobuyuki Yamamoto,Hiroshige Yoshioka,Masao Harada,Yuichiro Ohe,Naoyuki Nogami,Kengo Takeuchi,Tadashi Shimada,Tomohiro Tanaka,Tomohide Tamura +15 more
TL;DR: CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC, and the study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.